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Background: Although scientiﬁc knowledge about the beneﬁts of probiotic use in cystis ﬁbrosis (CF) is scarce, their expectative is promising. The
aim of this work was to analyze the effect of a Lactobacillus reuteri probiotic preparation versus placebo in CF patients.
Methods: A prospective, double blind, crossover and with placebo study was carried out in 30 CF patients from two Spanish hospitals. Patients were
randomized in Group A (6 months of probiotic followed by 6 months of placebo) and Group B (6 months of placebo followed by 6 months of
probiotic). GIQLI (gastrointestinal) and SF-12 (general) health tests were performed after probiotic and placebo intakes. Fat absorption coefﬁcient,
calprotectin, and inﬂammatory interleukin quantiﬁcation were determined in fecal samples. Total fecal DNA was obtained and metagenomic 454-
pyrosequencing was applied to analyze the microbiome composition. STATA v12 MP software was used for statistical analyses.
Results: Statistically signiﬁcant improvement in the gastrointestinal health and decrease of the calprotectin levels were demonstrated in patients after
probiotic exposure, in comparison with placebo. All CF subjects reported good tolerance to L. reuteriwithout secondary effects. Metagenomic analysis
showed an important dysbiosis in CF gut microbiota associated with a high concentration of Proteobacteria. Probiotic intake was followed by a
reduction in the total bacterial density, mostly due to a considerable reduction in the γ-Proteobacteria phylum; and an important increase of the microbial
diversity with a higher representation of Firmicutes.
Conclusions: Probiotics might ameliorate the dysbiosis of CF gut microbiota, characterized by a high density of Proteobacterial organisms. L. reuteri
signiﬁcantly decrease intestinal inﬂammation and increase digestive comfort.
© 2014 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Intestinal microbiota; Digestive health; Probiotics; Lactobacillus reuteri☆ Part of this work was presented as Oral Presentation in the 36th ECFC, Lisbon, 2013.
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The gastrointestinal tract is one of the most affected systems
in cystic fibrosis (CF) disease; pancreatic insufficiency is the
major associated pathology [1]. CF patients usually suffer
from maldigestion and fat malabsorption and both disorders
condition the subsequent steatorrhea. Since the 1980s, the
importance of a good nutritional status has been demonstrated
to improve the quality and quantity of life, as well as lung
infection management [2]. Nowadays, almost all CF patients
present an acceptable nutritional status mainly due to the use of
enzymatic replacement therapy (ERT), and an adequate fat
enrichment and hypercaloric diet which also limit the gastroin-
testinal symptoms [3]. However, a chronic gut inflammation
might influence their intestinal health status [4]. It is of note that a
good digestive food process not only is associated with intestinal
comfort, but more importantly influences the bacterial lung
colonization, the pulmonary failure and the survival rate [5].
Even though scientific knowledge about probiotic use in CF
remains scarce, their expectative is promising [6–9]. The main
target of probiotic strategies is to ameliorate the dysbiosis of gut
microbiota and its consequences, also including the conse-
quences derived from chronic antibiotic treatments [10]. In our
CF-Unit, probiotic consumption has been recommended since
the 1980s with high adherence and positive empiric results.
Nevertheless, the absence of prospective studies has precluded
the possibility of formulating standard recommendations.
The aim of this prospective and double blind study (including
placebo) was to assess the beneficial gastrointestinal properties of
probiotic consumption, and their effect in gut inflammation.
L. reuteri probiotic effects were assessed by pyrosequencing
tools for evaluating the resulting metagenomic effects in the gut
microbiota.
2. Materials and methods
2.1. Study design and patients
This is a double-blind multicenter study developed in two
geographically separate CF-Units of Spain (Madrid and
Granada). Thirty-nine CF patients were initially enrolled, and
30 completed the entire protocol (21 males and 9 females, age
range: 8–44 years, median age 17.7 years). The inclusion
criteria were fully informed CF patients older than 4 years who
consented (their parents if b18 years old) to participate in the
project and exclusion criteria included terminal stage of the
disease, acute pulmonary exacerbation acute exacerbation of
the lung infection, and/or immune deficient condition.
After the required signature of informed consent, patients
were randomized in Group A (starting with the administration
of probiotic during 6 months, followed by 6 months of placebo)
or Group B (starting with 6 months of placebo followed by
6 months of probiotic). Only the manufacturers knew the
significance of the product labels and the double blind code was
opened only at the end of the study. The study product used was a
chewable tablet containing 108 CFU of Lactobacillus reuteri
DSM17938. The dose administered was one tablet per day, as themanufacturer recommends. Active and placebo tablets and
packaging were identical and were kindly supported by Clinical
Research Manager Karin Diderot from BioGaia, Stockholm,
Sweden. The study was approved by the Clinical Ethics
Committee of our Hospital (HRyC-038/13).
2.2. Clinical variables
Anthropometric data, clinical status, antibiotic treatments,
hospital admittances and relevant clinical information were
prospectively collected. Gastrointestinal health was assessed
using the GIQLI test with 36 items concerning the gastrointes-
tinal symptoms, and their influence in social behavior and
emotions [11]. In addition, the general health status was
measured by the SF-12 tests with 12 items [12]. Both tests were
repeated twice by each patient, at the end of the probiotic (time
1) and placebo (time 2) intakes.
2.3. Fecal sampling and processing
Two fecal samples per individual were recovered after
probiotic (time 1) and placebo intakes (time 2). Samples were
processed at the University Hospital Ramón y Cajal following
the standard protocol used in the Biochemistry Department for
determinations of fat absorption measure by near-infrared
reflectance analysis (NIRA); fat absorption coefficient; calprotectin
quantification (Calprest, Eurospital, Trieste, Italy); and inflam-
matory interleukins (CBA, Becton Dickinson, Heidelberg,
Germany). Feces were immediately frozen after collection at
−80 ºC and stored until the sampling process ended. Defrost was
undertaken with a slow process at 4 ºC during 24 h in order to
avoid DNA fragmentation by drastic changes of temperature.
Total DNA was obtained from 0.5 g of feces completely
suspended in 5 ml of saline and centrifuged at low speed for
5 min; 1 ml of the upper phase was collected and total DNA was
obtained with a traditional manual protocol of extraction using
phenol/chloroform/isoamilic acid.
2.4. Metagenomic pyrosequencing
Metagenomic profiles were determined using tag-encoded
16S rRNA gene and were further pyro-sequenced at the
Centro Superior de Investigación en Salud Pública (CSISP),
Valencia University, Spain (http://www.csisp.gva.es/) by 454/
FLX Titanium (Roche). Bioinformatic analysis was developed
by Era7 Bioinformatics, Granada, Spain (http://www.era7.com/)
and nucleotide filiations were assigned using the Ribosomal
Database Project.
2.5. Statistical analysis
Normally distributed data were summarized using mean ±
SD while non-normal data was described using medians and
interquartile range (IQR). We used Shapiro–Wilks tests to
assess the normality of the underlying distribution of outcome
variables. We tested for carry-over effects by comparing the
differences between outcomes observed after placebo and
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and probiotics-placebo). In the absence of a significant carry-over
effect, we pooled the results of placebo and probiotics periods
and we made paired comparison of outcomes after the two
treatments. These comparisons were performed using parametric
paired t-test or non-parametric Wilcoxon signed rank sum tests
depending on underlying distributions. The magnitude of the
observed difference for each subject between both periods was
standardized using Cohen's D formula [13], and considering
≥0.2, ≥0.5, and ≥0.8 as small, medium and large effect sizes,
respectively. All analyses were performed using Stata v12 MP
and the significance level for all contrasts was established at 5%.
3. Results
Although 39 CF patients were enrolled, only 30 finished the
entire protocol, due to non-fulfillment (n = 5), vaginal candidi-
asis (n = 3), or acute pulmonary exacerbations (n = 1). The main
data are summarized in Table 1. It is important to note that the
adverse effects were not reported in any subject.
Having discarded any carry-over effect of probiotic prepara-
tion after 6 months of discontinuation, samples recovered after
6 months of placebo consumption were considered as equivalent
to “basal samples”. At the time of getting these basal samples,
our patients presented a good nutritional status with a body
mass index (BMI) median value of 19.9% (range 17.6–24.5%).
Although the FEV1 median value was 77% (range 32–118%),
eleven patients had ≥80%. Results on the GIQLI and the SF-12
tests were also satisfactory (Table 1). Eleven patients had
pancreatic insufficiency at the beginning of the study (66%).
Probiotic consumption was followed by statistically signifi-
cant changes in levels of calprotectin (33.8 vs. 20.3 μg/ml; p =
0.003) and non-significant variations in the inflammatory
parameters values (4 vs. 3.6 pg/ml for IL-8; 3.3 vs. 2.7 pg/ml
for TNFα and 2.3 vs. 2.4 pg/ml for IL-6), suggesting a tendency
towards a decrease in the gut inflammation (Table 1 and Fig. 1).Table 1
Summary of data collected after 6 months of probiotic or placebo intake.
Variable Placebo Probiotic P value
Weight a (kg) 48.2 ± 15.2 48.5 ± 14.9 0.95
Height (m) 1.6 ± 0.1 1.6 ± 0.1 0.18
BMI a 19.19 ± 2.9 19.26 ± 2.8 0.98
FEV1
a (%) 77.0 ± 24.1 74.6 ± 22.6 0.73
NIRA test (gr%) 4.9 ± 4.2 4.6 ± 4.2 0.20
Fat absorption coefficient (%) 96 ± 3.5 95 ± 2.9 0.38
SF-12 (range 0–100) 1.7 ± 0.2 1.6 ± 0.3 0.66
GIQLY 11.2 ± 0.3 11.4 ± 0.3 0.003
Calprotectin (μg/ml) 33.8 ± 23.5 20.3 ± 19.3 0.003
IL-8 (pg/ml) 4.0 ± 28.5 3.6 ± 4.4 0.38
IL-1β (pg/ml) 4.4 ± 41.5 4.4 ± 23.8 0.26
IL-6 (pg/ml) 2.3 ± 2.9 2.4 ± 3.5 0.91
IL-10 (pg/ml) 1.8 ± 2.4 1.9 ± 2.5 0.72
TNFα (pg/ml) 3.3 ± 6.4 2.7 ± 3.0 0.40
IL-12p70 (pg/ml) 3.0 ± 3.0 3.2 ± 4.8 0.33
a Normally distributed data expressed by mean ± standard deviation. The other
variables are non-normal and results expressed the median ± interquartile range.In agreement, statistically significant improvement of the gas-
trointestinal comfort was reflected in the GIQLI test results (p =
0.003) (Fig. 1). Using the Cohen's formula we classified the
positive effect size of the significant variables calprotectin (n =
22, 8 corresponding to small effect, 4 to medium effect and 10 to
large effect) and GIQLI (n = 24; 8 corresponding to small effect,
6 to medium effect and 9 to large effect). Correlation analysis
showed that in 19/30 patients both variables improved with a
large effect after the probiotic period (R2 = 0.055) (Fig. 2).
Metagenomic analysis of the fecal microbiota was carried
out in the 30 pairs of fecal samples, although finally only 25
pairs offered sufficient quality results, due to bad processing or
abundance of unspecific sequences. In comparison with what is
expected for normal healthy individuals (60% of Firmicutes,
25% of Bacteroidetes, 10% of Actinobacteria and 1.5% of
Fusobacteria) [14,15], basal metagenomic analysis in the 25
studied patients (considering as basal those fecal samples
collected after 6 months of placebo intake) exhibited an extreme
unbalance of CF gut microbiota phyla. Taking into account all
patients, in the basal status the predominant phylum was
Proteobacteria (68.2%), followed by Actinobacteria (14.4%),
Firmicutes (18.0%), and finally Bacteroidetes (3.6%). Important
changes were observed after the probiotic intake period, especially
a decrease of Proteobacteria (30.7%), with a considerable increase
of Firmicutes (38.2%), and Bacteroidetes (16.9%) (Figs. 3 and 4).
Almost all nucleotide sequences of the Proteobacteria phylum
corresponded to the γ-Proteobacteria class, Enterobacteriales
order. Nucleotidic sequences compatible with the Pseudomonas
aeruginosa species or the Pseudomonas genera were extremely
unusual.
After probiotic intake, a wider bacterial families diversity
was observed in feces, combined with a concomitant reduction
in the 16S rDNA sequences density (630 ± 3353.6 vs. 1221 ±
4653.6), without statistical significance. A complete analysis of
metagenomic results of each individual patient was carried out
considering their age, nutritional status, frequency of pulmo-
nary exacerbation episodes, antibiotic intake, and pancreatic
sufficiency, without detecting specific associations.
One of the most interesting results in this work is the finding
of the high density of γ-Proteobacteria phylum in the CF fecal
samples, apparently in detriment of Firmicutes and Bacteroidetes
(Figs. 3 and 4). The apparent predominance of γ-Proteobacteria
in a few number of probiotic-exposed patients was generally
associated with a strong decrease in total bacterial cells measured
by the total 16S rDNA copies (Patients 19, 21, 10, 3, 14, 26, 1, 15,
30, 25, 11, and 8 in decreasing order). There was a high
individual variability in the proportion of phyla, and different
patterns were also observed in different individuals after probiotic
intake. A tendency to increased bacterial diversity was detectable.
Significant correlation between γ-Proteobacteria density varia-
tions and age, gender, mutation filiations, clinical or inflamma-
tion improvements was not detected.
4. Discussion
The nutritional status optimization in CF patients is one of
the most important targets and is also crucial for the function
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Fig. 1. Individual differences in the GIQLY score and in the calprotectin values between the placebo (basal) and the probiotic periods for the 30 subjects. The
statistical analysis was based on Wilcoxon test.
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undernourishment and underweight, but currently substitutive
therapies permit reaching an acceptable nutritional condition
for almost all individuals. Initially, our patients presented a satis-
factory nutritional status (BMI = 19.19 ± 2.9), although most of
them referred to bad and uncomfortable digestions, attributable to
pancreatic insufficiency, alteration of billiard salts secretion, fat
malabsorption, and the bacterial overgrowth. The structure of
intestinal microbiota of CF patients is probably shaped by the
microecological effects resulting from these alterations in gut
functions, and also by the increased local concentrations of anti-
microbials, either secreted by bile or accessing the intestinal tract-1,50   
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Fig. 2. Correlation between the effect size (negative effect , small effect , mediu
variables following Cohen's D formula.after inhalation [16]. Such alterations in the microbiota might in
their turn influence the digestive health, but this possibility has
been scarcely explored in CF [6,8,10].
In this context, probiotics might represent an “ecological”
alternative to improve the functionality of gut microbiota [6]. In
our CF-Unit the use of probiotics has been promoted since the
1980s, but the lack of scientific observations prevented the
development of specific guidelines. In fact, many individual
patients have a preferred presentation and formulation. The pos-
itive empiric results observed by our team during the last years
have encouraged us to obtain scientific data that corroborate these
observations.y = 0,1708x + 0,2857
R² = 0,055
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Fig. 3. Distribution of themain bacterial phyla in the cystic fibrosis gut microbiota,
before and after probiotic consumption, in comparison with a “physiological”
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induces a significant decrease of the gut inflammatory marker
calprotectin and an increase of the intestinal comfort. Our positive
outcomes in a controlled, double blind, including placebo studyNo. Subject 21 9 3 20 6 15 19 18 10 4 26 8 22 25 30
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attending our CF-Units, as other authors have previously suggested
[6–8].
Another important issue was that probiotic prevents vulvo-
vaginal candidiasis in women. A frequent perception among
our female patients was the “spontaneous” control of genital
candidiasis while they were consuming probiotics, and the
relapse of symptoms immediately after interrupting probiotic
intake. In our work, three patients abandoned the study due to
the development of vulvovaginal candidiasis. After the
double-blind process was opened, it was corroborated that all
three patients left the protocol during the placebo period, in
concordance with the patients' perception. Probiotics for
vulvovaginosis caused by Candida species control has been
previously recommended [17].
All bacterial communities of the gut microbiota are affected
by the disease and their evolution, in a clear connection with
the lung microbiota [10,18,19]. Recently it has been pointed the
possibility that the genetic background of the patients might be
related to the gut dysbiosis, particularly in F508del homozy-
gosis [14]. The existence of an abnormal gut microbiota in CF
patients has been recently documented [16,18,19,21,23], evenClostridia
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(TGGE, Q-PCR, microarrays, and species specific PCR). The
metagenomic approach is considered as the best option for the
analysis of the intestinal microbiota [22]. Duytschaever et al.,
also described in CF patients the enrichment of the enterobac-
terial counts inside a gut microbiota with poor species diversity
in comparison with their siblings [23]. The enrichment of the
Proteobacteria had been previously corroborated by in a
CF-murine model [21], whereas the Bifidobacteria and the
Clostridium cluster XIVa were clearly underrepresented [15].
The potentially beneficial organism Bdellovibrio bacteriovorus
was found in lower proportion in CF patients [24].
The need of establishing standard parameters that might
define a “healthy microbiota” in human adults has motivated a
growing consensus between different consortiums with a world-
wide acceptation of 60% of Firmicutes, 25% of Bacteroidetes, and
15% of minority phyla [20]. In our study, dysbiosis is mainly
produced by the relative increase of the Proteobacteria phylum;
fifteen of our patients (60%) exhibited Proteobacteria densities
higher than 50% (Fig. 3). The effect of the prolonged probiotic
consumption was also reflected in the Firmicutes density increase
from 18% in the placebo stage to 38.2% after the probiotic period
(Fig. 3). Schippa et al. recently demonstrated that the gut CF
dysbiosis is related to the CFTRmutation type, also demonstrating
a clear predominance of Enterobacteriaceae [14]. In agreement
with our work, Enterobacteriaceae are the predominant order
within γ-Proteobacteria, and their concentration could also be
related to the CFTR genetic mutation. Other related factors that
might be considered to establish the cause of the dysbiosis are
the frequent antibiotic exposure [25], the persistent diarrheas
and motility alterations, and the classically described bacterial
overgrowth in the small intestine.
In summary, probiotics could be an ecological alternative to
improve the functionality of CF gut microbiota, which exhibited a
considerable dysbiosis with high rates of Proteobacterial organ-
isms.We demonstrated that in comparisonwith placebo, L. reuteri
significantly decrease the intestinal inflammation and increase the
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